119,279 Shares in Hims & Hers Health, Inc. $HIMS Bought by Pathway Capital Management LP

Pathway Capital Management LP purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 119,279 shares of the company’s stock, valued at approximately $6,766,000. Hims & Hers Health comprises about 33.3% of Pathway Capital Management LP’s holdings, making the stock its largest holding.

A number of other hedge funds have also made changes to their positions in HIMS. Jones Financial Companies Lllp raised its stake in shares of Hims & Hers Health by 24.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 27,237 shares of the company’s stock valued at $1,591,000 after acquiring an additional 5,371 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in Hims & Hers Health by 9.0% in the 3rd quarter. Principal Financial Group Inc. now owns 673,213 shares of the company’s stock valued at $38,185,000 after purchasing an additional 55,315 shares during the period. Mutual Advisors LLC acquired a new stake in Hims & Hers Health during the third quarter worth about $248,000. Thrivent Financial for Lutherans boosted its stake in Hims & Hers Health by 2.9% during the third quarter. Thrivent Financial for Lutherans now owns 47,782 shares of the company’s stock worth $2,710,000 after buying an additional 1,338 shares in the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of Hims & Hers Health by 81.8% in the 3rd quarter. Privium Fund Management B.V. now owns 40,000 shares of the company’s stock worth $2,269,000 after buying an additional 18,000 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on HIMS shares. Bank of America upped their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday, November 4th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 29th. Barclays initiated coverage on Hims & Hers Health in a research report on Monday, December 8th. They set an “overweight” rating and a $48.00 price target for the company. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Finally, Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research note on Monday, January 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have issued a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $42.62.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $26.45 on Tuesday. The stock has a 50 day moving average of $34.11 and a 200 day moving average of $44.09. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. Hims & Hers Health, Inc. has a 12 month low of $23.97 and a 12 month high of $72.98. The company has a market capitalization of $6.02 billion, a price-to-earnings ratio of 48.97, a PEG ratio of 4.46 and a beta of 2.37.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). The firm had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims & Hers Health’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same period last year, the company posted $0.32 earnings per share. As a group, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health announced that its Board of Directors has authorized a stock buyback plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 13,750 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares of the company’s stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares in the company, valued at $226,684.25. The trade was a 53.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 131,974 shares of company stock worth $4,763,800. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.